SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $275,415 | -29.7% | 18,968 | +1.4% | 0.00% | 0.0% |
| Q2 2023 | $391,558 | +40.3% | 18,708 | +41.5% | 0.00% | 0.0% |
| Q1 2023 | $279,164 | -17.0% | 13,218 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $336,398 | +9.2% | 13,218 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $308,000 | +25.2% | 12,808 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $246,000 | +10.8% | 12,808 | +0.1% | 0.00% | – |
| Q1 2022 | $222,000 | -20.7% | 12,798 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $280,000 | +22.8% | 12,798 | +7.1% | 0.00% | – |
| Q3 2021 | $228,000 | +11.2% | 11,949 | 0.0% | 0.00% | – |
| Q2 2021 | $205,000 | -1.4% | 11,949 | +28.3% | 0.00% | – |
| Q1 2021 | $208,000 | +2.0% | 9,312 | +1.7% | 0.00% | – |
| Q4 2020 | $204,000 | – | 9,152 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |